Clinical Trial Update: Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating exemestane with or without ATN-224 in postmenopausal women with recurrent or advanced breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ATN-224
• Exemestane (Exemestane)

Snippet

Sponsor: Cancer Research UK | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED